ClinicalTrials.gg

Program

simepdekinra

Also written as “LY4100511 (DC-853)”, “LY4100511” and “LY4100511 (DC-853) Dose 1”.

Its studies are mostly in Psoriasis, led by Eli Lilly.

Furthest: phase 2, since Sep 16, 20247 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly70 open or runningphase 2since Sep 16, 2024Mar 8, 2024none ahead
  • Named in Eli Lilly’s own pipeline as Simepdekinra, phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 8, 2024First studies: 2 phase 1 studies in HealthyFirst studyNCT06311656, NCT06345794
  2. Jul 10, 2024Phase 1 study in HealthyNCT06503679 · 49 enrolled · United States
  3. Sep 12, 2024Phase 1 study in HealthyNCT06627088 · 24 enrolled · United States
  4. Sep 16, 2024Phase 2 study in Plaque PsoriasisNCT06602219 · 222 enrolled · United States, Canada, Czechia and more
  5. Apr 2, 20252 phase 1 studiesNCT06916143, NCT06937411

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06937411Healthy · United Kingdom1CompletedOct 30, 202388
NCT06916143Healthy Participants · United States1TerminatedApr 8, 20251
NCT06602219Plaque Psoriasis · United States, Canada, Czechia and more2CompletedJul 24, 2025222
NCT06627088Healthy · United States1CompletedDec 31, 202424
NCT06503679Healthy · United States1CompletedDec 31, 202449
NCT06345794Healthy · United States1CompletedJun 18, 202450
NCT06311656Healthy · United States1CompletedOct 4, 202469

How it is read

Names in the registry

  • “LY4100511 (DC-853)”, 5 entries
  • “LY4100511”, 3 entries
  • “LY4100511 (DC-853) Dose 1”, 1 entry
  • “LY4100511 (DC-853) Dose 2”, 1 entry
  • “LY4100511 (DC-853) Dose 3”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.